Medipost to Invest USD 15 Million in US Subsidiary for Cartistem Phase 3 Trial

PUBT · 3d ago
Medipost to Invest USD 15 Million in US Subsidiary for Cartistem Phase 3 Trial
  • Medipost’s board resolved on October 29, 2026, to make an additional investment in its wholly owned US subsidiary, MEDIPOST.
  • The cash investment totals KRW 20.04 billion for 15,000,000 shares, representing 8% of equity.
  • Funding will support US Phase 3 research and development for knee osteoarthritis stem-cell therapy Cartistem, alongside operating capital.
  • Completion is scheduled for November 30, 2026, bringing ownership to 157,000,000 shares while retaining a 100% stake.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medipost Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261029900801), on October 29, 2026, and is solely responsible for the information contained therein.